Endometrial Cancer: Chemoradiotherapy Versus Chemo Alone

​ Because endometrial carcinoma is a heterogeneous disease, it is often difficult to treat, and women diagnosed with advanced disease are at risk for local and systemic recurrence. When researchers tested platinum-based chemotherapy plus radiation therapy against chemotherapy alone in patients with stage III or IVA endometrial carcinoma to see which treatment improved outcomes the most, they discovered that chemoradiotherapy did not improve outcomes more so than chemotherapy alone. This study, r...
Continue reading

Optimizing Oral Chemotherapy Patient Education With Robin Esposito, RN, BSN, OCN®

​ Because oral chemotherapy agents are administered by the patient at home without direct supervision from a nurse, patients often call with questions and concerns about their medications. Seeking to prevent lost time and patient confusion, Robin Esposito, RN, BSN, OCN®, undertook a project aimed at improving communication and education regarding oral chemotherapy agents for patients in ambulatory care settings. In this interview with i3 Health, Ms. Esposito discusses the implementation and resu...
Continue reading

Adjuvant Capecitabine Effective in Biliary Tract Cancer

​ With a five-year overall survival rate under 10%, the outlook is poor for individuals diagnosed with biliary tract cancer. Only 20% of patients are eligible for surgical resection with the intent to cure the disease. In addition, until this point, no studies have identified a beneficial adjuvant therapy. In order to remedy this problem, the researchers of the BILCAP study (EudraCT 2005-003318-13), a phase 3 clinical trial featuring a collaboration of 44 specialist hepato-pancreato-biliary cent...
Continue reading

Adding Docetaxel to Androgen Suppression and Radiotherapy in High-Risk Prostate Cancer: An Interview With Seth A. Rosenthal, MD, FACR, FASTRO

Of the 20% of patients with prostate cancer who have high-risk disease, around 30% to 40% experience a relapse following initial treatment. Less than 50% of these patients are cured. A phase 3 clinical trial, the NRG Oncology trial NRG-RTOG 0521, reports a way to improve survival for patients with nonmetastatic, high-risk prostate cancer: adding docetaxel to a standard regimen consisting of radiotherapy (RT) and long-term androgen suppression (AS) . In this interview with i3 Health, Seth A. Rose...
Continue reading

High-Risk Prostate Cancer: Adding Docetaxel Increases Survival

A phase 3 clinical trial reports that adding docetaxel to a standard regimen consisting of radiotherapy and long-term androgen suppression (AS) therapy improves outcomes for men with high-risk nonmetastatic prostate cancer. In the United States, prostate cancer is the second leading cause of cancer-related death among men. Of the 20% of patients whose prostate cancer is considered high risk, around 30% to 40% experience a relapse following initial treatment. Less than 50% of these patients are c...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.